Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 26, 2018

Abbott launches new point-of-care test for HIV management

Abbott has launched a new point-of-care test called m-PIMA HIV-1/2 VL in the Netherlands for quick, accurate and easy management of human immunodeficiency virus (HIV) infection.

Abbott has launched a new point-of-care test called m-PIMA HIV-1/2 VL in the Netherlands for quick, accurate and easy management of human immunodeficiency virus (HIV) infection.

Said to be the first test for viral load measurement at point-of-care, the new technique delivers results within 70 minutes and thereby enables screening and treatment in a single visit.

For monitoring ART treatment failure, viral load testing is considered to be the benchmark. According to the World Health Organization (WHO), every person receiving ART should undergo a viral load test at 6 months and 12 months, and annually after that, if the individual is stable on ART.

"Said to be the first test for viral load measurement at point-of-care, the new technique delivers results within 70 minutes and thereby enables screening and treatment in a single visit."

Abbott Rapid Diagnostics, Infectious Disease-Emerging Markets vice-president Damian Halloran said: “Abbott is committed to delivering HIV diagnostic solutions that support the UNAIDS agenda and enable life-saving decisions that have a profound impact on people and society.

“The m-PIMA HIV-1/2 VL is an example of how Abbott is focused on delivering tools that empower healthcare providers and their patients where and when they need it most.”

m-PIMA HIV-1/2 VL expands the company’s portfolio of diagnostic solutions intended for HIV care across more than 120 countries, including all 55 African countries.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The quantitative nucleic acid amplification test is designed to measure the viral load of HIV-1 groups M/N and O, as well as HIV-2 in plasma samples.

It can be used on the portable m-PIMA platform and facilitates data point connectivity to support decentralised programme management.

Abbott’s HIV portfolio also includes a quantitative assay called RealTime HIV-1 developed to identify HIV-1 virus in blood spots or plasma samples obtained from infected individuals.

The in-vitro reverse transcription-polymerase chain reaction (RT-PCR) assay is intended to offer improved precision and accurate monitoring.

Related Companies

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU